Skip to main content

Advertisement

Table 4 Ongoing clinical trials of EGF816

From: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Phase Study population NCT no.
Phase I/II Patients with EGFR mutated solid malignancies 02108964
Phase Ib/II Patients with EGFR mutated NSCLC 02335944
Phase II Patients with EGFR mutated and cMET-positive NSCLC 02323126
  1. EGFR: epidermal growth factor receptor, NSCLC: non-small cell lung cancer, TKI: tyrosine kinase inhibitor